Forget taking a pill a day. Canada is using psychedelics to revolutionize the way we treat mental health and addiction

1w
15m read
Summary

It’s not working.” Selkirk is also the co-founder of Sansero, a psilocybin life sciences company that’s developing psilocybin-based treatments for mental health disorders, inflammation and addiction. Michael Verbora, who is also the Chief Medical Officer for Alefia Health, a cannabis company. This is the backdrop for a revival in psychedelic research. Bruce Linton, considered by many to be one of the architects of Canada’s cannabis industry, is also an investor with the company. Before Mind Medicine Inc. rang the bell at Toronto’s NEO Exchange last week, signalling the arrival of the world’s first publicly traded psychedelic company, they held a moment of silence.

Article Preview

Before Mind Medicine Inc. rang the bell at Toronto’s NEO Exchange last week, signalling the arrival of the world’s first publicly traded psychedelic company, they held a moment of silence. 

It was Stephen Hurst’s idea. Hurst, who has worked in biopharmaceuticals for 35 years, co-founded the company with JR Rahn, a Silicon Valley tech executive who previously worked at Uber, in 2019. Together they are part of a growing movement that’s pushing neuro-pharmaceuticals and psychedelics into the mainstream. 

Hurst has brought a secret weapon to Mind Med. For more than two decades, his research team has been developing a derivative of ibogaine,...

Read the full article @ The Growth Op